ইস্রায়েল - হিব্রু - Ministry of Health

rafa laboratories ltd - fentanyl - מדבקות - fentanyl 12.5 mcg/hour

ইস্রায়েল - হিব্রু - Ministry of Health

rafa laboratories ltd - fentanyl - מדבקות - fentanyl 25 mcg/hour - fentanyl

ইস্রায়েল - হিব্রু - Ministry of Health

rafa laboratories ltd - fentanyl - מדבקות - fentanyl 50 mcg/hour - fentanyl

ইস্রায়েল - হিব্রু - Ministry of Health

rafa laboratories ltd - fentanyl - מדבקות - fentanyl 50 mcg/hour - fentanyl

ইস্রায়েল - হিব্রু - Ministry of Health

rafa laboratories ltd - fentanyl - מדבקות - fentanyl 75 mcg/hour - fentanyl

ইস্রায়েল - হিব্রু - Ministry of Health

neopharm scientific ltd - catumaxomab 100 mcg/ml - concentrate for solution for infusion - catumaxomab - intraperitoneal treatment of malignant ascites in patients with epcam-positive carcinomas where standard therapy is not available or no longer feasible.

ইস্রায়েল - হিব্রু - Ministry of Health

rafa laboratories ltd - calfactant as phospholipid - תרחיף - calfactant as phospholipid 35 mg/ml - lung surfactants - infasurf is indicated for the prevention of respiratory distress syndrome (rds) in premature infants at high risk for rds and for the treatment ("rescue") of premature infants who develop rds. infasurf decreases the incidence of rds mortality due to rds and air leaks associated with rds. prophylaxis : prophylaxis therapy at birth with infasurf is indicated for premature infants <29 weeks of gestational age at significant risk for rds. infasurf prophylaxis should be administered as soon as possible preferably within 30 minutes after birth. treatment: infasurf therapy is indicated for infants 72 hours of age with rds (confirmed by clinical and radiologic findings) and requiring endotracheal intubation.

ইস্রায়েল - হিব্রু - Ministry of Health

ש.שוורץ באר שבע בעמ - לחות העור סביב העיניים

ইস্রায়েল - হিব্রু - Ministry of Health

שמן מרוקאי ישראל בעמ - טיפול לקרקפת יבשה

ইস্রায়েল - হিব্রু - Ministry of Health

שמן מרוקאי ישראל בעמ - טיפול לקרקפת יבשה